Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Sales | 131,314 | 196,245 | 241,544 | 163,562 | 120,282 |
| Cost of Goods | 10,512 | 52,827 | 62,176 | 30,419 | 11,347 |
| Gross Profit | 120,802 | 143,418 | 179,368 | 133,143 | 108,935 |
| Operating Expenses | 109,372 | 141,208 | 75,693 | 96,062 | -697,794 |
| Operating Income | 11,942 | 3,037 | 103,851 | 37,500 | 807,076 |
| Interest Expense | 656 | 1,799 | 19,619 | 27,415 | 35,745 |
| Other Income | 52,374 | 34,773 | -12,027 | -8,793 | 25,308 |
| Pre-tax Income | 63,660 | 36,011 | 72,205 | 1,292 | 796,639 |
| Income Tax | 9,841 | 41,230 | -4,148 | -5,306 | 167,337 |
| Net Income Continuous | 53,819 | -5,219 | 76,353 | 6,598 | 629,302 |
| Net Income Discontinuous | -1,665 | -28,142 | -19,215 | -9,583 | N/A |
| Net Income | $52,154 | $-33,361 | $57,138 | $-2,985 | $629,302 |
| EPS Basic Total Ops | 3.02 | -1.98 | 3.44 | -0.18 | 33.13 |
| EPS Basic Continuous Ops | 3.11 | -0.31 | 4.59 | 0.41 | 33.13 |
| EPS Basic Discontinuous Ops | -0.10 | -1.67 | -1.16 | -0.59 | N/A |
| EPS Diluted Total Ops | 2.94 | -1.98 | 3.31 | -0.18 | 31.85 |
| EPS Diluted Continuous Ops | 3.03 | -0.31 | 4.43 | 0.39 | 31.85 |
| EPS Diluted Discontinuous Ops | -0.09 | -1.67 | -1.11 | -0.57 | N/A |
| EPS Diluted Before Non-Recurring Items | 2.91 | 1.94 | 4.65 | 3.13 | 2.11 |
| EBITDA(a) | $47,431 | $55,157 | $171,600 | $90,022 | $870,521 |